Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Molecular Pathogenesis of B-cell Malignancies
share announcement

Molecular Pathogenesis of B-cell Malignancies

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 9090

Special Issue Editor

Dr. Lai N. Chan

E-Mail Website
Guest Editor
Department of Cancer Biology, Cleveland Clinic Main Campus, Cleveland, OH 44196, USA
Interests: cancer biology; hematology; B-cell malignancies; leukemia; lymphoma; signal transduction; metabolism

Special Issue Information

Dear colleagues,

B-cell malignancies are one of the most common types of cancer in adults. The use of genetic analyses has improved diagnosis, classification, prognosis, and therapeutic decision-making. Over the past decade, advances in the “omics” approaches have provided important insights into disease progression of B-cell malignancies.

This Special Issue of Biomedicines will focus on “Molecular Pathogenesis of B-cell Malignancies”, with the aim to provide an overview of the current understanding of (1) how metabolic activity evolves during disease progression of B-cell leukemia and lymphomas, (2) how dysregulated signaling pathways and crosstalk among these pathways can modulate disease progression, (3) and how genetic and epigenetic alterations can drive the development of B-cell malignancies.

Dr. Lai N. Chan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • B-cell leukemia
  • lymphoma
  • molecular pathogenesis
  • metabolic reprogramming
  • oncogenic signaling
  • genetic landscape
  • epigenetics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 1934 KiB  
Article
Unmutated IGHV1-69 CLL Clone Displays a Distinct Gene Expression Profile by a Comparative qRT-PCR Assay
by Selena Mimmi, Domenico Maisano, Vincenzo Dattilo, Massimo Gentile, Federico Chiurazzi, Alessandro D’Ambrosio, Annamaria Zimbo, Nancy Nisticò, Annamaria Aloisio, Eleonora Vecchio, Giuseppe Fiume, Enrico Iaccino and Ileana Quinto
Biomedicines 2022, 10(3), 604; https://doi.org/10.3390/biomedicines10030604 - 4 Mar 2022
Cited by 1 | Viewed by 2409
Abstract
Chronic Lymphocytic Leukemia (CLL) is a heterogeneous disease characterized by variable clinical courses among different patients. This notion was supported by the possible coexistence of two or more independent CLL clones within the same patients, identified by the characterization of the B cell [...] Read more.
Chronic Lymphocytic Leukemia (CLL) is a heterogeneous disease characterized by variable clinical courses among different patients. This notion was supported by the possible coexistence of two or more independent CLL clones within the same patients, identified by the characterization of the B cell receptor immunoglobulin (BcR IG) idiotypic sequence. By using the antigen-binding site of the BcR IG as bait, the identification and isolation of aggressive and drug-resistance leukemic B-cell clones could allow a deeper biological and molecular investigation. Indeed, by the screening of phage display libraries, we previously selected a peptide binder of the idiotypic region of CLL BCR IGs expressing the unmutated rearrangement IGHV1-69 and used it as a probe to perform a peptide-based cell sorting by flow cytometry in peripheral blood samples from patients with CLL. Since the IGHV1-69 clones persisted during the follow-up time in both patients, we explored the possibility of these clones having acquired an evolutive advantage compared to the other coexisting clones in terms of a higher expression of genes involved in the survival and apoptosis escape processes. To this end, we studied the expression patterns of a panel of genes involved in apoptosis regulation and in NF-kB-dependent pro-survival signals by comparative qRT-PCR assays. According to the results, IGHV1-69 clones showed a higher expression of pro-survival and anti-apoptotic genes as compared to the other CLL clones with different immunogenetic characteristics. Moreover, these IGHV1-69 clones did not carry any characteristic genetic lesions, indicating the relevance of our approach in performing a comprehensive molecular characterization of single tumor clones, as well as for designing new personalized therapeutic approaches for the most aggressive and persistent tumor clones. Full article
(This article belongs to the Special Issue Molecular Pathogenesis of B-cell Malignancies)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 1129 KiB  
Review
Resveratrol and Its Role in the Management of B-Cell Malignancies—A Recent Update
by Dhruv Sanjay Gupta, Vaishnavi Gadi, Ginpreet Kaur, Meena Chintamaneni, Hardeep Singh Tuli, Seema Ramniwas and Gautam Sethi
Biomedicines 2023, 11(1), 221; https://doi.org/10.3390/biomedicines11010221 - 15 Jan 2023
Cited by 8 | Viewed by 2842
Abstract
The growing incidence of B cell malignancies globally has prompted research on the pharmacological properties of phytoconstituents in cancer management. Resveratrol, a polyphenolic stilbenoid widely found in nature, has been explored for its anti-inflammatory and antioxidant properties, and promising results from different pre-clinical [...] Read more.
The growing incidence of B cell malignancies globally has prompted research on the pharmacological properties of phytoconstituents in cancer management. Resveratrol, a polyphenolic stilbenoid widely found in nature, has been explored for its anti-inflammatory and antioxidant properties, and promising results from different pre-clinical studies have indicated its potential for management of B cell malignancies. However, these claims must be substantiated by a greater number of clinical trials in diverse populations, in order to establish its safety and efficacy profile. In addition to this, there is a need to explore nanodelivery of this agent, owing to its poor solubility, which in turn may impact its bioavailability. This review aims to offer an overview of the occurrence and pathogenesis of B cell malignancies with a special focus on the inflammatory pathways involved, the mechanism of actions of resveratrol and its pharmacokinetic profile, results from pre-clinical and clinical studies, as well as an overview of the marketed formulations. The authors have also presented their opinion on the various challenges associated with the clinical development of resveratrol and future perspectives regarding therapeutic applications of this agent. Full article
(This article belongs to the Special Issue Molecular Pathogenesis of B-cell Malignancies)
►▼ Show Figures

Figure 1

16 pages, 1197 KiB  
Review
Dysregulation of Small Nucleolar RNAs in B-Cell Malignancies
by Martijn W. C. Verbeek, Stefan J. Erkeland and Vincent H. J. van der Velden
Biomedicines 2022, 10(6), 1229; https://doi.org/10.3390/biomedicines10061229 - 24 May 2022
Cited by 6 | Viewed by 3089
Abstract
Small nucleolar RNAs (snoRNAs) are responsible for post-transcriptional modification of ribosomal RNAs, transfer RNAs and small nuclear RNAs, and thereby have important regulatory functions in mRNA splicing and protein translation. Several studies have shown that snoRNAs are dysregulated in human cancer and may [...] Read more.
Small nucleolar RNAs (snoRNAs) are responsible for post-transcriptional modification of ribosomal RNAs, transfer RNAs and small nuclear RNAs, and thereby have important regulatory functions in mRNA splicing and protein translation. Several studies have shown that snoRNAs are dysregulated in human cancer and may play a role in cancer initiation and progression. In this review, we focus on the role of snoRNAs in normal and malignant B-cell development. SnoRNA activity appears to be essential for normal B-cell differentiation and dysregulated expression of sno-RNAs is determined in B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, B-cell non-Hodgkin’s lymphoma, and plasma cell neoplasms. SnoRNA expression is associated with cytogenetic/molecular subgroups and clinical outcome in patients with B-cell malignancies. Translocations involving snoRNAs have been described as well. Here, we discuss the different aspects of snoRNAs in B-cell malignancies and report on their role in oncogenic transformation, which may be useful for the development of novel diagnostic biomarkers or therapeutic targets. Full article
(This article belongs to the Special Issue Molecular Pathogenesis of B-cell Malignancies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop